In the past decade, clinical outcomes for patients with unresectable hepatocellular carcinoma have improved. Liver cirrhosis is present in most cases, affecting prognosis and treatment safety. Clinical trials for immunotherapies excluded patients with moderate liver dysfunction, leading to debate about treatment options. A study compared outcomes of patients with moderate liver dysfunction receiving immunotherapy or best supportive care. Immunotherapy was associated with significantly lower risk of death. The findings suggest potential benefits of immunotherapy for patients with moderate liver dysfunction. While the study is retrospective, it may inform future clinical trials. These results provide important evidence for treatment decisions in this patient population.
Source link
How to Manage Unresectable HCC With Liver Dysfunction
